Ventricular Tachycardia Mechanisms
ConditionVentricular Tachycardia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorEmory University
About this trial
The purpose of this study is to understand why certain hearts have ventricular arrhythmias and help identify areas of the heart that cause arrhythmias. There is still a significant gap in understanding why ventricular arrhythmias occur. This study will examine the electrical properties of the heart tissue to understand how these arrhythmias occur, and hopefully identify areas that might lead to ventricular arrhythmias. The hope is that studying this might be able to improve outcomes during ventricular tachycardia (VT) ablations.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of ischemic cardiomyopathy
Single or dual chamber implantable cardioverter-defibrillator (ICD)
Disqualifiers
Non-Ischemic cardiomyopathy
Contraindication to catheter ablation
Severe peripheral arterial disease or medical condition that prohibit arterial access
Ventricular tachycardia (VT) or sudden cardiac arrest (SCA) within 30 days of acute coronary syndrome or within 90 days of coronary revascularization
Trial design
Design model
Single group
Treatments tested in this trial
Monophasic Action Potential (MAP) Catheter
DeviceThe EasyMap catheter is a temporary quadripolar catheter for recording monophasic action potentials and for intracardiac pacing. During a standard of care VT ablation, the MAP catheter will be used to study cellular action potential of the ventricular myocardium, which cannot be done on traditional catheters. The catheter is placed on the myocardium (similar to other traditional catheters) and a recording signal is transmitted to the workstation. Using the MAP catheter the will not interrupt or distort any of the standard treatment procedures.
Treatment groups
10 Participants
are divided into 1 treatment groupGroup A: Monophasic Action Potential (MAP) CatheterExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Waveform Morphology
Identification of sites that are critical to reentry of ventricular tachycardia from bystander sites will be performed by analyzing local ventricular activation. Local ventricular action is assessed with waveform morphology and is measured in voltage (mV). The normal range is \>3 mV bipolar and \>8.3 mV unipolar.
Time frame
During ablation on Day 12
Conduction Velocity
Identification of sites that are critical to reentry of ventricular tachycardia from bystander sites will be performed by analyzing electrophysiological properties. Electrophysiological properties are assessed with conduction velocity, measured in meters per second (m/s).
Time frame
During ablation on Day 1Secondary outcomes
1
Identify mechanisms of slowed conduction at ILAM
The mechanisms responsible for slowed conduction at sites that are critical to ventricular tachycardia using monophasic action potential signals will be examined.
Time frame
During ablation on Day 12
Identify surrogate markers
Surrogate markers for monophasic action potential tracings will be compared to conventional mapping catheters.
Time frame
During ablation on Day 1Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov